Lucentis®
Ranibizumab is a humanized monoclonal antibody fragment (Fab) that inhibits VEGF-A. Pioneer in intravitreal anti-VEGF therapy.
| Dosage Form | Intravitreal Injection (Solution) |
| Strength | 0.5 mg/0.05mL; 0.3 mg/0.05mL |
| Storage | Store at 2–8°C. Protect from light. Do not freeze. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Wet AMD; macular edema following RVO; DME; diabetic retinopathy; myopic choroidal neovascularization.
Fab fragment that binds all active isoforms of VEGF-A, preventing VEGF receptor binding and inhibiting endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Each Burrard Pharmaceuticals technology transfer package for Ranibizumab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.